Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial Meeting Abstract
| Authors: | Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; DiSimone, C.; Shaffer, D. R.; Sarrió, R. G.; Ribe, S. G.; Wu, J.; Schmidt, E. V.; Kubiak, P.; Okpara, C.; Smith, A. D.; Motzer, R. J. |
| Abstract Title: | Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120302241 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.e16542 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: e16542 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work